CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.
about
Genomic profiling in triple-negative breast cancerNanomedicine-Mediated Therapies to Target Breast Cancer Stem CellsNeoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancerCarbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.Locoregional recurrence after neoadjuvant chemotherapy.Effects of metformin on CD133+ colorectal cancer cells in diabetic patientsClinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series.Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis.Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer.Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors.An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasivenessEvaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer".PLC-β2 is modulated by low oxygen availability in breast tumor cells and plays a phenotype dependent role in their hypoxia-related malignant potential.Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari".Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC.Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast.CD133 mediates the TGF-β1-induced activation of the PI3K/ERK/P70S6K signaling pathway in gastric cancer cells.Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.Higher expression of EpCAM is associated with poor clinical and pathological responses in breast cancer patients undergoing neoadjuvant chemotherapy.Aldehyde dehydrogenase 1 as a predictor of the neoadjuvant chemotherapy response in breast cancer: A meta-analysis
P2860
Q27015775-D33A2E91-F43C-4134-953E-DE0962E67A2FQ28066297-7BC2CFEF-A55C-4775-80E8-DB856BF2543DQ28706276-0A6375AD-C6C4-41AB-9F21-C6C1AAAF56EBQ33759404-E6EDCFE9-BDEC-4EA3-B74E-D953DE147291Q33972948-1B836B20-AC86-463B-8BAF-00925FA27D1CQ35053962-57C8EE53-B705-455A-A352-E0E80ADB29E0Q35132045-21498709-384D-4374-9C94-6077560C4E11Q36024666-AADCDEB7-E570-42F7-B861-FD4C3B9BF592Q36292530-11A57CDC-4DF5-4F8F-BC92-2F0F4E77A06CQ36441530-32D7602B-7B51-4758-9B81-8B7446F76431Q36544248-DBF8BD5C-2819-4603-BBA8-A7629E34FECBQ36771879-90264CC7-6A36-4F45-B74E-BA0A607A3A82Q37399964-62BA34E7-4AC6-4E1B-AE57-0CD0F356C90CQ37513954-FC528F64-00D6-473D-96ED-A7082355FA61Q39900695-5CA22163-B3D7-449E-8669-2B87469BB5C3Q40088702-7B371573-752D-4A48-9E03-D937187AA7C2Q41350562-BE1D9338-3137-4BFE-973A-187DA08D5A04Q41611344-59489B2E-0B54-4EB9-9B17-8111065B6E73Q44473846-6D8982C5-677F-4F07-9D66-853DA19A479EQ49238339-A9194306-61EB-4F12-ACC0-85C44063DEA4Q50983817-90824BD8-0561-44FF-98A6-A54BC1236907Q53130487-FE179DB0-5D05-4E2C-A503-38134A3D16B5Q57108835-BB13AF43-5087-448B-88E4-EF9C7D31ED5D
P2860
CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@ast
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@en
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@nl
type
label
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@ast
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@en
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@nl
prefLabel
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@ast
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@en
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@nl
P2093
P2860
P1433
P1476
CD133 is a useful surrogate ma ...... chemotherapy in breast cancer.
@en
P2093
Kenichi Wakasa
Kosei Hirakawa
Masahiko Ohsawa
Masakazu Yashiro
Naoki Aomatsu
Shinichiro Kashiwagi
Tetsuro Ishikawa
Tsutomu Takashima
P2860
P304
P356
10.1371/JOURNAL.PONE.0045865
P407
P577
2012-09-25T00:00:00Z